IRTC Stock Risk & Deep Value Analysis
iRhythm Holdings, Inc
DVR Score
out of 10
What You Need to Know About IRTC Stock
We analyzed iRhythm Holdings, Inc using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran IRTC through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Moderate. Here's what we found.
How Risky Is IRTC Stock?
Overall Risk
Moderate
Financial Risk
Medium
Market Risk
Medium
Competitive Risk
Medium
Execution Risk
Medium
Regulatory Risk
High
What Are the Red Flags for IRTC?
- ⚠
Negative changes in CMS reimbursement policies (e.g., rates or coverage criteria)
- ⚠
Increased competitive intensity from new market entrants or established players (e.g., Apple, Philips)
- ⚠
Unfavorable regulatory reviews or delays for new product features/indications
- ⚠
Q1 2026 earnings miss or weak forward guidance
Unlock IRTC Red Flags & Risk Warnings
Create a free account to see the full analysis
Is IRTC Stock Undervalued?
Unlock the full AI analysis for IRTC
Get the complete DVR score, risk analysis, and more
Does IRTC Have a Competitive Moat?
Sign in to unlockMoat Rating
🛡️ Narrow
Moat Trend
Expanding
Moat Sources
4 Identified
The moat is strengthening due to iRhythm's growing proprietary dataset, which fuels its AI algorithms and improves diagnostic accuracy, making it increasingly difficult for new entrants to replicate. Physician trust and established reimbursement also contribute to its durability.
Moat Erosion Risks
- •Disruptive technology from large tech companies (e.g., smartwatches with medical-grade ECG capabilities)
- •Changes in healthcare policy that favor lower-cost, less comprehensive monitoring solutions
- •Intense competition from well-capitalized medical device companies
IRTC Competitive Moat Analysis
Sign up to see competitive advantages
What Could Drive IRTC Stock Higher?
Near-Term (0-6 months)
- •Q1 2026 Earnings Report (Estimated Early May 2026)
- •Continued Zio AT adoption acceleration metrics
- •Clinical data releases for Zio AT in new patient populations
Medium-Term (6-18 months)
- •Major international market entry progress (e.g., Germany, Japan)
- •Expanded reimbursement coverage for specific indications or geographies
- •Strategic partnerships with large healthcare systems or payers
Long-Term (18+ months)
- •Dominant market share in remote cardiac monitoring
- •Expansion into new diagnostic or preventative cardiac care segments
- •AI-driven insights leading to personalized arrhythmia management
Catalysts & Growth Drivers
Upgrade to Premium to see catalysts
What's the Bull Case for IRTC?
- ✓
Consistent >20% annual revenue growth and improving gross margins
- ✓
Clear progress towards sustained positive free cash flow and GAAP profitability
- ✓
Successful expansion into new international markets and new product indications
- ✓
Retention of key reimbursement codes and favorable regulatory outcomes
Bull Case Analysis
See what could go right with Premium
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for IRTC (iRhythm Holdings, Inc) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.
